“I am very happy to present these data, showing that women with many previous implantation failures have a chance of becoming parents”
The European Society of Human Reproduction and Embryology (ESHRE) is meeting right now in Istanbul, Turkey. Swedish fertility and transplantation specialist company Vitrolife has seen clinical data relating to its EmbryoGlue® technology published at the event, and issued a press release trumpeting the results. The study suggest that use of the novel medium increases both implantation and pregnancy rates, regardless of hormone stimulation of the endometrium or not.
EmbryoGlue® is a patent protected medium, enriched with hyaluronan, a natural substance abundant in all tissues in the body. It has a unique combination of a high concentration of hyaluronan and recombinant albumin. EmbryoGlue® is used when transferring embryos into the woman as the final step of an IVF treatment.
The prospective, randomised study investigated whether the preparation method of the endometrium, the lining of the uterus, before transfer had an effect on pregnancy rate.
The study included 203 patients under the age of 40, all with four or more previous implantation failures. 101 of the women had embryo transfer in a natural ovulation cycle, and 102 women were prepared by hormone replacement cycle. Patients in each group were allocated to transfer with either EmbryoGlue® or a transfer medium with no hyaluronan.
The study showed that the pregnancy rate increased significantly for the group receiving transfer in EmbryoGlue®. In the group with natural cycles it increased from 10% to 31.4% and in the group receiving transfer in a hormone stimulated cycle from 15.7% to 41.2%.
The use of EmbryoGlue® for embryo transfer has been previously analysed in numerous studies, showing an increased treatment success independent of patient age, day of transfer. This study now suggests that its efficacy is also independent of endometrial preparation.
“I am very happy to present these data, showing that women with many previous implantation failures have a chance of becoming parents,” says Japanese investigator Dr. Nakagawa, who performed the study.
Source: Vitrolife AB., Business Wire